A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Single Level Cervical Disc Disease

计划入组 284 人 · 首次发布于 2020 年 8 月 20 日

A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous Levels

计划入组 300 人 · 首次发布于 2020 年 9 月 25 日

Post-Market, Long-Term Follow Up of Mobi-C® Cervical Disc for One and Two Level Treatment of Cervical Disc Disease

计划入组 216 人 · 首次发布于 2017 年 3 月 13 日

X-Synergy®

NanoLithium® NP03

Integra®-SC

C & C Oxygen Company

United States

Buchanan C Michael

United States

DENVER NEPHROLOGISTS P C

United States

Spineart's BAGUERA® C Cervical Disc Prosthesis Meets Non-Inferiority Thresholds in Both 1-Level and 2-Level IDE Studies

Tandem Diabetes Secures FDA Approval for Mobi Android App, Stock Surges 20%

ViroGates and Sobi Expand Collaboration on suPARnostic® Diagnostic for Kineret® Treatment